studies

HEPATOLOGY, VOLUME 62, NUMBER 1 (SUPPL) AASLD ABSTRACTS 727A
Christoph Sarrazin - Advisory Committees or Review Panels: Bristol-Myers
Squibb, Janssen, Merck/MSD, Gilead, Roche, Abbvie, Janssen, Merck/MSD;
Consulting: Merck/MSD, Merck/MSD; Grant/Research Support: Abbott, Roche,
Merck/MSD, Gilead, Janssen, Abbott, Roche, Merck/MSD, Qiagen; Speaking
and Teaching: Gilead, Novartis, Abbott, Roche, Merck/MSD, Janssen, Siemens,
Falk, Abbvie, Bristol-Myers Squibb, Achillion, Abbott, Roche, Merck/MSD, Janssen
The following authors have nothing to disclose: Simone Susser, Christoph P. Berg,
Caterina Berkowski
1056
Hepatocellular carcinoma development in hepatitis C
virus patients who achieved sustained viral response by
interferon therapy: a large scale, long-term cohort study
Yuko Nagaoki, Hiroshi Aikata, Hiromi Kan, Hatsue Fujino, Tomoki
Kobayashi, Takayuki Fukuhara, Keiichi Masaki, Takashi Nakahara,
Tomokazu Kawaoka, Masataka Tsuge, Akira Hiramatu,
Michio Imamura, Yoshiiku Kawakami, Hidenori Ochi, Kazuaki
Chayama; Department of Gastroenterology and Metabolism, Hiroshima
University, Hiroshima, Japan
Background We assessed risk factors for the development of
hepatocellular carcinoma (HCC) following successful eradication
of hepatitis C virus (HCV) with interferon therapy in a longterm,
large-scale cohort study. Methods We reviewed 2262
consecutive patients with HCV infection who achieved sustained
viral response (SVR) by interferon therapy between January
1995 and September 2013 in our study group. Among them,
1094 patients who met the following inclusion criteria were
enrolled in this retrospective cohort study: 1) received HCC
surveillance by tumor markers (AFP, DCP), ultrasonography
and/or dynamic computed tomography at least biannually; 2)
underwent histological examination with liver biopsy before
IFN therapy; and 3) with no evidence of HCC development
prior to HCV eradication and within a year following eradication.
We assessed host, pre-IFN treatment, and post-treatment
risk factors associated with HCC development among these
SVR patients. Results 1) Patients included 585 males aged 11
to 85 years (median 60) at the time of HCV eradication. 581
patients had HCV genotype 1b, and 513 had genotypes 2a,
2b or other genotypes. 936 patients had interferon lambda 3
(IFNL3) SNP rs8099917 genotype TT, and 158 had genotypes
GG or TG. 885 patients had DEPDC5 SNP rs1012068 genotype
TT, and 209 had genotype GG or TG. Histological fibrosis
stage before IFN treatment was as follows: F0 or F1, 492;
F2, 39; F3, 174; and F4, 34. 2) During the observation period
(median 50 months: range 13-224), 36 (3%) of 1094 patients
developed HCC after HCV eradication. The median period
from HCV eradication to HCC development was 37 months
(range 17-141), and the cumulative rates of developing HCC
at 5,10 and 15 years were 4%, 6% and 12%, respectively. 3)
As independent risk factors for HCC development, multivariate
analysis identified older age ≥ 60 years (HR, 3.1: 95%CI,
1.3-6.6: P=0.009), male sex (HR, 11.9: 95%CI, 2.8-50.0:
P